A new trading day began on Friday, with Gain Therapeutics Inc (NASDAQ: GANX) stock price up 12.34% from the previous day of trading, before settling in for the closing price of $1.54. GANX’s price has ranged from $0.95 to $3.19 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -37.02%. Meanwhile, its annual earnings per share averaged 30.90%. With a float of $34.19 million, this company’s outstanding shares have now reached $35.95 million.
Let’s determine the extent of company efficiency that accounts for 25 employees. In terms of profitability, gross margin is -77.34%, operating margin of -20973.43%, and the pretax margin is -21686.75%.
Gain Therapeutics Inc (GANX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Gain Therapeutics Inc is 4.90%, while institutional ownership is 10.53%.
Gain Therapeutics Inc (GANX) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.17 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.67% during the next five years compared to -37.02% drop over the previous five years of trading.
Gain Therapeutics Inc (NASDAQ: GANX) Trading Performance Indicators
Here are Gain Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Gain Therapeutics Inc (GANX)
Looking closely at Gain Therapeutics Inc (NASDAQ: GANX), its last 5-days average volume was 0.53 million, which is a jump from its year-to-date volume of 0.27 million. As of the previous 9 days, the stock’s Stochastic %D was 47.59%.
During the past 100 days, Gain Therapeutics Inc’s (GANX) raw stochastic average was set at 31.25%, which indicates a significant decrease from 45.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1492 in the past 14 days, which was lower than the 0.1514 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6850, while its 200-day Moving Average is $1.9280. However, in the short run, Gain Therapeutics Inc’s stock first resistance to watch stands at $2.0633. Second resistance stands at $2.3967. The third major resistance level sits at $2.6733. If the price goes on to break the first support level at $1.4533, it is likely to go to the next support level at $1.1767. Now, if the price goes above the second support level, the third support stands at $0.8433.
Gain Therapeutics Inc (NASDAQ: GANX) Key Stats
With a market capitalization of 62.19 million, the company has a total of 35,949K Shares Outstanding. Currently, annual sales are 0 K while annual income is -20,410 K. The company’s previous quarter sales were 0 K while its latest quarter income was -4,530 K.
